Skip to main content

Table 2 Univariable analysis of potential risk factors for severe restenosis after therapeutic bronchoscopy

From: Association of the location and initial degree of malignant central airway stenosis with the risk of severe restenosis after interventional bronchoscopy

Variables

Severe restenosis

P value

No (n = 141)

Yes (n = 92)

Age (y), (mean ± SD)

65.9 ± 8.7

67.6 ± 7.3

0.123

Gender, n (%)

   

  Male

126 (89.4)

88 (95.7)

0.086

  Female

15 (10.6)

4 (4.3)

 

Diabetes, n (%)

   

  Yes

7 (5.0)

4 (4.3)

0.828

  No

134 (95.0)

88 (95.7)

 

Hypertension, n (%)

   

  Yes

39 (27.7)

19 (20.7)

0.227

  No

102 (72.3)

73 (79.3)

 

COPD, n (%)

   

  Yes

13 (9.2)

8 (8.7)

0.891

  No

128 (90.8)

84 (91.3)

 

Dyspnea index, n (%)

  

0.618

  0

26 (18.4)

16 (17.4)

 

  1

5 (3.5)

4 (4.3)

 

  2

16 (11.3)

11 (12.0)

 

  3

22 (15.6)

8 (8.7)

 

  4

72 (51.1)

53 (57.6)

 

Initial degree of MCAS, (mean ± SD, %)

72.3 ± 25.0

83.9 ± 20.4

< 0.001

Post-intervention residual stenosis, (mean ± SD, %)

26.1 ± 17.8

31.8 ± 15.9

0.012

Location of the lesion, n (%)

  

< 0.001

  Trachea

31 (22.0)

3 (3.3)

 

  Left main bronchus

39 (27.7)

36 (39.1)

 

  Right main bronchus

41 (29.1)

37 (40.2)

 

  Right intermediate bronchus

30 (21.3)

16 (17.4)

 

Histological types, n (%)

  

0.463

  Lung adenocarcinoma

4 (2.8)

1 (1.1)

 

  Lung squamous cell carcinoma

108 (76.6)

78 (84.8)

 

  SCLC

12 (8.5)

5 (5.4)

 

  Other*

17 (12.1)

8 (8.7)

 

Other treatments after intervention,** n (%)

  

0.366

  0

34 (24.1)

16 (17.4)

 

  1

45 (31.9)

36 (39.1)

 

  ≥ 2

62 (44.0)

40 (43.5)

 
  1. COPD chronic obstructive pulmonary disease, MCAS malignant central airway stenosis, SCLC small-cell lung carcinoma
  2. *Other histological types including adenoid cystic carcinoma, lymphoma, large cell neuroendocrine carcinoma, mesenchymal tumor, soft tissue sarcoma, and metastatic malignancies (esophageal cancer, gastric cancer, colorectal adenocarcinoma, and thyroid papillary carcinoma)
  3. **Other treatments including radiotherapy, chemotherapy, molecule-targeted therapy, and immunotherapy. 0, patients didn’t receive any other treatment after therapeutic bronchoscopy; 1, patients received one other treatment after therapeutic bronchoscopy; ≥ 2, patients received at least two other treatments after therapeutic bronchoscopy